Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
April 14, 2026

Lonvo-z / lonvoguran ziclumeran for prevention of hereditary angioedema attacks as of April 2026

MARA Rating Company April 14, 2026

Kineret / anakinra for treating Still’s disease as of March 2021

MARA Rating Company April 14, 2026

Leqembi / lecanemab for early AlzheimerÕs Disease as of March 2026

MARA Rating Company March 7, 2026

Gomekli / mirdametinib for symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type 1 as of March 2026

MARA Rating Company March 7, 2026

Zegfrovy for non-small cell lung cancer with EGFR Exon 20 insertion as of March 2026

MARA Rating Company March 7, 2026

Treosulfan for preparative conditioning for allogeneic stem cell transplant in AML/MDS as of March 2026

MARA Rating Company March 7, 2026

Vimseltinib / romvimza for in symptomatic tenosynovial giant cell tumor as of March 2026

MARA Rating Company March 7, 2026

Sibeprenlimab-szsi / voyxact for reducing proteinuria in adults with primary IgA nephropathy as of February 2026

MARA Rating Company February 28, 2026

Ibtrozi / taletrectinib for locally Advanced or Metastatic ROS1-Positive NSCLC as of February 2026

MARA Rating Company February 28, 2026

Emrelis / telisotuzumab vedotin-tllv for previously Treated High c-Met Overexpressing Non-Squamous NSCLC as of February 2026

MARA Rating Company February 28, 2026